*.*.44.201
药智数据企业版
量身打造,体验升级
立即前往
VIP免费试用申请
登录 注册
当前位置: 首页 > 反馈纠错 帮助中心
N-甲基哌嗪
CAS号 109-01-3
中文别名 1-甲基哌嗪; N-甲基哌嗪 ; 甲基哌嗪; N-甲哌【口+井】; 1-甲基哌嗪, 98+%; N-甲基哌嗪,98%; N-METHYLPIPERAZINE(N-甲基
英文别名 N-METHYLPIPERAZINE; NMPRZ; 1-methyl-piperazin; Piperazine,1-methyl-; LABOTEST-BB LTBB000517; methylpiperazine; METHYLPIPERAZINE-N哌嗪)
分子量 100.16
分子式 C5H12N2
EINECS编号 203-639-5
综合信息 查看供应
目录导航
提示:点击目录可直接跳转到对应的信息。

N-甲基哌嗪物理化学性质

密度 0.903
熔点 -6 oC
沸点 138 oC
折射率 1.4645-1.4665
闪点 42 oC
水溶性 可溶
无色液体。沸点138℃(140℃),相对密度0.903(20/4℃),折光率1.4378,闪点42℃,溶于水、乙醚、乙醇,与水、甲醇等任意比互溶,在水溶液中呈弱碱性。

N-甲基哌嗪产品用途

有机合成中间体。在医药工业中用于制取抗菌素类药物甲哌利福霉素、抗精神病药三氟拉嗪等。主要用作氧氟沙星、氯氮平、西地那非、吐立抗、佐匹克隆等药物的中间体,亦可用于农药、染料、塑料等行业。
用于制取抗菌类药物甲哌利福霉素、抗精神病药三氟拉嗪及氧氟沙星等



N-甲基哌嗪生产方法

由六水哌嗪经甲基化反应而得。将六水哌嗪及盐酸加入反应锅中,加热至45℃,滴加甲酸和甲醛的混合液。加毕,在50℃左右反应2-3h,再升温回流,至二氧化碳气体不再逸出为止。冷却至80℃,加入盐酸,加热蒸酸至干。稍冷后加入甲醇,加热回流30min,趁热过滤(滤渣为哌嗪二盐酸盐)。滤液回收甲醇至尽,残液加入氢氧化钠溶液至pH=14,蒸馏,得含水甲基哌嗪。加苯加热回流带水至尽,分馏,收集132-140℃馏分,得无水甲基哌嗪。收率约50%。

安全术语
S16 Keep away from sources of ignition.
远离火源。
S26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
不慎与眼睛接触后,请立即用大量清水冲洗并征求医生意见。
S36 Wear suitable protective clothing.
穿戴适当的防护服。
S45 In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
若发生事故或感不适,立即就医(可能的话,出示其标签)。
S36/37/39 Wear suitable protective clothing, gloves and eye/face protection.
穿戴适当的防护服、手套和护目镜或面具。
风险术语
R10 Flammable.
易燃。
R21 Harmful in contact with skin.
与皮肤接触有害。
R23 Toxic by inhalation.
吸入有毒。
R34 Causes burns.
引起灼伤。
R36/37/38 Irritating to eyes, respiratory system and skin.
刺激眼睛、呼吸系统和皮肤。
下游产品
Pefloxacin; RB 1589; EU 5306; Peflacin; PeflacineFleroxacin; Ro-23-6240/000; Ro-236240; AM-833; Megalocin; Megalosin; Megalone; QuinodisFleroxacin; Ro-23-6240/000; Ro-236240; AM-833; Megalocin; Megalosin; Megalone; QuinodisMetitepine; Methiothepin; Ro-8-6837(maleate); VUFB-6276(mesylate)BTM-1086(HCl); BTM-1042Difloxacin hydrochloride; A-56619; ABBOTT-56619Amifloxacin; Win-493753(mesylate); Win-49375Fluperlapine; NB-106689Telenzepine hydrochloride; SK-871; B-818-04(hemifumarate); B-803-32(free base); B-818-03Pipecuronium bromide; RGH-1106; ArduanLoprazolam mesylate; HR-158; RU-31158; Havlane; DormonoctOfloxacin; Hoe-280; DL-8280; Exocin; Exocine; Ocuflox; Floxin; TarividLevofloxacin; HR-355; RWJ-25213; DR-3355; Iquix; Oftaquix; Quixin; Tavanic; Levaquin; Floxacin; CravitDizocilpine; MK-801(maleate); L-640689; Neurogard(maleate)KB-5246KB-5246KW-3635Sipatrigine; 619C89; 619C; BW-619C89Pibrozelesin hydrochloride; KW-2189Pibrozelesin hydrochloride; KW-2189Olanzapine; LY-170053; Zyprexa Zydis; Zyprexa Velotab; Midax; Olansek; Zyprexa; LanzacOlanzapine; LY-170053; Zyprexa Zydis; Zyprexa Velotab; Midax; Olansek; Zyprexa; LanzacOlanzapine; LY-170053; Zyprexa Zydis; Zyprexa Velotab; Midax; Olansek; Zyprexa; LanzacSildenafil citrate; UK-92480-10; UK-92480(free base); Penegra; Patrex; Wan Ai Ke; ViagraSildenafil citrate; UK-92480-10; UK-92480(free base); Penegra; Patrex; Wan Ai Ke; ViagraSildenafil citrate; UK-92480-10; UK-92480(free base); Penegra; Patrex; Wan Ai Ke; ViagraAzimilide hydrochloride; NE-10064; StedicorLurtotecan; OSI-211(Liposomal formulation); NX-211(Liposomal formulation); GW-211; GG-211; GI-147211C(diHCl); GI-147211Lurtotecan; OSI-211(Liposomal formulation); NX-211(Liposomal formulation); GW-211; GG-211; GI-147211C(diHCl); GI-147211Lurtotecan; OSI-211(Liposomal formulation); NX-211(Liposomal formulation); GW-211; GG-211; GI-147211C(diHCl); GI-147211Flumezapine; LY-120363FR-161282MDL-75204DA ((-)-enantiomer); MDL-74722DA ((+)-enantiomer); MDL-74180DAMDL-75204DA ((-)-enantiomer); MDL-74722DA ((+)-enantiomer); MDL-74180DAFandofloxacin hydrochloride; DW-116DMP-777; L-694458DMP-777; L-694458DMP-777; L-694458GMC2-83RSD-992ST-1455(free base)SB-272183BM-212NSC-712392; LB-42908Eszopiclone; (+)-Zopiclone; (S)-Zopiclone; EstorraEszopiclone; (+)-Zopiclone; (S)-Zopiclone; EstorraY-931Y-931CB-300919CWJ-a-5Bosutinib;bosutinib monohydrate;SKI-606GW-569180AGW-569180AGW-569180ACRX-395A-422885.66; BSF-466895DB-51838YM-176770RPR-238677BVT-2733A-420983Tozasertib; VX-680;MK-0457Imatinib mesylate; GGP-57148B; STI-571; CGP-57148(free base); Gleevec; GlivecDovitinib LactateENMD-2076;ENMD-981693 (as free base)ENMD-2076;ENMD-981693 (as free base)Ponatinib hydrochloride;Ponatinib;AP-24534Ofloxacin; Hoe-280; DL-8280; Exocin; Exocine; Ocuflox; Floxin; TarividLevofloxacin; HR-355; RWJ-25213; DR-3355; Iquix; Oftaquix; Quixin; Tavanic; Levaquin; Floxacin; CravitSotrastaurin;AEB-071;NVP-AEB-071Onvansertib fumarate;NMS-1286937;NMS-P937;PCM-075;67RM91WDHQ (UNII code)Trilaciclib hydrochloride;Trilaciclib;G1T28;G1T28-1Bomedemstat tosylate;IMG-7289;IMG-241 bis-tosylate salt;2PYF2U9JNF (UNII)Bomedemstat tosylate;IMG-7289;IMG-241 bis-tosylate salt;2PYF2U9JNF (UNII)Ponatinib;AP24534Entrectinib;RXDX-101;RO7102122;entrektinib;RG6268;RozlytrekErtugliflozin;ertugliflozin-l-pyroglutamic acid;MK-8835;Steglatro;PF-04971729